Medicine NewsGenzyme Corp. (NASDAQ: GENZ) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) announced that data from the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) were presented at the European Society of Cardiology’s Congress 2010 in Stockholm, Sweden…
Comments Off
Naringenin, an antioxidant derived from the bitter flavor of grapefruits and other citrus fruits, may cause the liver to break down fat while increasing insulin sensitivity, a process that naturally occurs during long periods of fasting…
Comments Off
Impax Laboratories, Inc. (NASDAQ: IPXL) today confirms that it has initiated a challenge of patents listed by MSP Singapore Co. LLC in connection with VYTORIN® (ezetimibe/simvastatin), 10 mg/80 mg. Impax filed its Abbreviated New Drug Application (“ANDA”) containing a paragraph IV certification for a generic version of VYTORIN® with the U.S. Food & Drug [...]
Comments Off
Imagine this: order a cheeseburger and fries, and pick up a free cholesterol-busting statin tablet along with the other free condiments, that’s what a group of UK researchers suggests you should be able to do at fast food outlets as a way to offset the increase in heart attack risk from eating junk [...]
Comments Off
Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, announced that its MARINE trial, a Phase 3 clinical trial of AMR101, has completed patient enrollment and randomization into the treatment phase of this trial…
Comments Off
Abbott has received U.S. Food and Drug Administration (FDA) approval for two new dosage strengths of SIMCOR®, a cholesterol medication. The new SIMCOR dosage strengths combine 40 mg of simvastatin – the most commonly prescribed dose of simvastatin – with either 500 mg or 1,000 mg of niacin extended-release…
Comments Off
Young people with even modestly elevated cholesterol levels are more likely to develop coronary artery calcium and atherosclerosis later in life, according to a 20-year study released on August 2 by UCSF researchers…
Comments Off
Abbott received U.S. Food and Drug Administration (FDA) approval for two new dosage strengths of SIMCOR®, a cholesterol medication. The new SIMCOR dosage strengths combine 40 mg of simvastatin – the most commonly prescribed dose of simvastatin – with either 500 mg or 1,000 mg of niacin extended-release…
Comments Off
No firm conclusions about HDL cholesterol can be drawn from JUPITER sub-analysis Sophia Antipolis, 23 July 2010: The European Society of Cardiology (ESC) is concerned that interpretations of a paper about cholesterol, published in the Lancet (1), could act to deter ongoing research efforts into developing new therapeutic strategies to increase high density lipoprotein [...]
Comments Off
American Academy of Family Physicians – Coca-Cola Alliance, Conflict of Interest or Ethical Relationship? In an essay addressing the recent controversy over the American Academy of Family Physicians accepting a large corporate donation from The Coca-Cola Company to fund patient education materials on obesity prevention, family physician and AAFP member Howard Brody, M.D., Ph.D…
Comments Off